LSUHSC – OCHSNER
ONCOLOGY PROGRAM

Follow Up Retreat

Friday, March 6, 2009

Ochsner Medical Center
Brent House Hotel
New Orleans, LA
OBJECTIVES

1. Obtain information on the Status of the LSUHSC-OCHSNER Oncology Program.
2. Evaluate group activities since Sept 27th retreat.
3. Discuss upcoming activities for groups.
4. Learn from newly started collaborations.

AGENDA

12:00 – 12:10: Update  
Dr. John Cole & Dr. Augusto Ochoa

12:10 – 12:15: Opportunities for Clinical Research Collaboration  
Dr. Adam Riker

12:15 – 12:25: Tissue Banking & Archival Tissue Utilization  
Dr. Adam Riker

12:25 – 12:45: IRB Issues  
Dr. Ken Kratz (LSUHSC) & Dr. Joe Breault (Ochsner)

12:45 – 1:40: Learning from New Collaborations  
12:45 – 1:00 Lung, Head and Neck:  
Dr. B. Boulmay & Dr. R. Walvekar
1:00 – 1:10 Leukemia and Lymphoma:  
Dr. P. Rodriguez & Dr. Y. S. Choi
1:10 – 1:20 Dr. T. Lin & Dr. Y. S. Choi
1:20 – 1:30 Melanomas:  
Dr. E. Davila & Dr. A. Riker
1:30 – 1:40 Ochsner-LSU on HIV/AIDS Malignancies  
Dr. J. Phillips

1:40 – 2:00: Open Discussion on Improving Collaborations
1. Discuss Biorepository
2. Postgraduate course agenda/curriculum
3. Summary of current activities
4. Annual schedule

Priority 1 – Tissue biorepository

1. What is needed
2. Purpose
3. Automated
4. Consent
5. Clinical Correlation
6. Coordination
7. Backups
8. Advisory – (Pathology, Surgery, Administration, Scientists, OC)
9. Coordination with pathology

Priority 2 – Communications

1. Listserv
2. Dinner (1 per year)
3. Quarterly meeting (Dec 12, 2:30 to 5:00 PM), Present Operations (2 hours), Rotate LSU-Ochsner
4. Fellows/PhD Research
   a. Surgery (1 yr research)
   b. Colorectal (1 yr research)
5. Design a postgraduate course
6. Video link
7. Grant writing/and grant submission

Priority 3 – Recruitment

- Ochsner Surgery – 1 Surgeon
- LSU-Ochsner Basic Scientists
- Joint Recruitment
- LSU Surgery
- Other (GI Pathology, Rad. Onc)
- LSU (Medical Oncology)

Priority 4 – Research Collaboration

1. “Early Stage Carcinogenesis Model”
   a. In vivo: Boulares
   b. In Vitro –
   c. Tissue Procurement: Bolton, Beck, Way

Priority #5

“Diet, Inflammation, and Carcinogenesis”

- Animal model: Boulares, Kim
- In vitro/ ex vivo
- Patients: Wey, Beck
Prostate/GU

Group Reporter: Shahriar Koochekpour, MD, PhD

1. Intra & Inter-institutional
2. Clinical Participation and Commitment
   a. Recognition of interested clinicians
   b. Biospecimen collection
   c. Use Ochsner Pathology Tissue Bank
   d. One-One collaboration
3. Expansion of PCG to GU-group
   (Monthly Meetings/alternative)
4. LSU Biostat/Epidem involvement in:
   a. Planning Research
   b. Grant Activity
   c. Publication
5. IRB agreement LSU + Ochsner (?)
6. Focus on minority research subjects/biospecimen
7. Long term goal: Translational Clinical Trials

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Check Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collins</td>
<td>Sean</td>
<td>X</td>
</tr>
<tr>
<td>Koochekpour</td>
<td>Shahriar</td>
<td>X</td>
</tr>
<tr>
<td>Liu</td>
<td>Wanguo</td>
<td>X</td>
</tr>
<tr>
<td>Mandal</td>
<td>Diptasri</td>
<td>X</td>
</tr>
<tr>
<td>Mercante</td>
<td>Donald</td>
<td>X</td>
</tr>
<tr>
<td>Simonsen</td>
<td>Neal</td>
<td>X</td>
</tr>
<tr>
<td>Su</td>
<td>Joseph</td>
<td>X</td>
</tr>
<tr>
<td>Zabaleta</td>
<td>Jovanny</td>
<td>X</td>
</tr>
<tr>
<td>Zea</td>
<td>Arnold</td>
<td>X</td>
</tr>
</tbody>
</table>
Lung, Head, and Neck

Group Reporter: Abbas Abbas, MD

1. Patient Management Guidelines
2. Gene Therapy of NET
3. Protein + MRNA assays with NET
4. NET-Dendmter (?) Cell Factor
   a. OCT vs No-OCT Net PX
   b. Pre & Post Op
   c. Other Tumor Types

Short Term Goals

1. Communication
   a. Collect e-mails, phones
   b. Start a correspondence group
2. Regular Meetings
   a. Monthly
   b. Place, alternate
   c. Forum – 30 minute presentation, bring ideas

Long Term Goals

1. Start database of lung CA + Head/Neck
2. Survey for lung cancer patients including population-based info
3. Prospective Biorepository (Genomics and Proteomics)
4. Accelerate Clinical Trial Accrual
Leukemia, Lymphoma, and HIV Related
Group Reporter - Mohamed Elmongy, MD, MPH, DSc

Hematological Malignancies

1. Combined Transgenic/Animal Model Core Facility at Ochsner (Startup Pilot Funding)
2. Tissue/Liquid Sample Research Pathologist – Repository at LSUHSC – Staff Support
3. IRB – Dual recognition
   Universal Consent (Like MD Anderson)
4. Meetings
   a. Internally once/every 2 weeks
   b. Once monthly (LSU/Ochsner)
   c. Translational Oncology Grand Rounds
      i. Access Grid (Monthly)
5. Set up E-Room Home Base
6. E-library at LSUHSC – Access for Ochsner Faculty
7. GMP Facility Participation
8. Annual Retreat LSU/Ochsner

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Check Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aliyar</td>
<td>Ashok</td>
<td>X</td>
</tr>
<tr>
<td>Brown</td>
<td>Archie</td>
<td>X</td>
</tr>
<tr>
<td>Choi</td>
<td>Yong Sung</td>
<td>X</td>
</tr>
<tr>
<td>Cui</td>
<td>Yan</td>
<td>X</td>
</tr>
<tr>
<td>Davila</td>
<td>Eduardo</td>
<td>X</td>
</tr>
<tr>
<td>Elmongy</td>
<td>Mohamed</td>
<td>X</td>
</tr>
<tr>
<td>Li</td>
<td>Li</td>
<td>X</td>
</tr>
<tr>
<td>Luftig</td>
<td>Ronald</td>
<td>X</td>
</tr>
<tr>
<td>Phillips</td>
<td>Joseph</td>
<td>X</td>
</tr>
<tr>
<td>Prakash</td>
<td>Orn</td>
<td>X</td>
</tr>
<tr>
<td>Rodriguez</td>
<td>Paulo</td>
<td>X</td>
</tr>
<tr>
<td>Vedekis</td>
<td>Wayne</td>
<td>X</td>
</tr>
<tr>
<td>Yoon</td>
<td>Sun-Ok</td>
<td>X</td>
</tr>
</tbody>
</table>
Breast and Cervical
Group Reporter – John Cole, MD

Projects: Short Term

1. Collaborations around tissue
   a. Fresh tissue (tumor and normal)
   b. Serum
   c. Archival tissue (paraffin)
2. Nipple Aspirate
3. Pathology assistance – IHC Slide Review

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Check Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alahari</td>
<td>Suresh</td>
<td>X</td>
</tr>
<tr>
<td>Catling</td>
<td>Andrew</td>
<td>X</td>
</tr>
<tr>
<td>Cole</td>
<td>John</td>
<td>X</td>
</tr>
<tr>
<td>Desai</td>
<td>Shyamal</td>
<td>X</td>
</tr>
<tr>
<td>Hagensee</td>
<td>Michael</td>
<td>X</td>
</tr>
<tr>
<td>Huh</td>
<td>Kyung Won</td>
<td>X</td>
</tr>
<tr>
<td>Kousoulas</td>
<td>Gus</td>
<td>X</td>
</tr>
<tr>
<td>Ouhtit</td>
<td>Allal</td>
<td>X</td>
</tr>
<tr>
<td>Raj</td>
<td>Madhwa</td>
<td>X</td>
</tr>
<tr>
<td>Worthylake</td>
<td>David</td>
<td>X</td>
</tr>
</tbody>
</table>
Neuroendocrine and Other Group Reporter – Lowell Anthony, MD

Short Term

I. Phase I
   a. Viral Vector
   b. Pharmaceutical

II. Phase II & III
   - Streamline IRB (Common Pathway)
   - Research Pathology Core
   - General Electronic Database of Cell Lines Available
   - Phase I Facility
   - Forum for Interaction
     o Video Conferencing
     o Regular Interactive Conferences
   - Have co-investigators for grants at both institutions

Long Term

1. Prognostic Genomics -> Personalization Medicine (Holy Grail)
2. Prognostic Staging System (TN-v M-v) – mTOR inhibitor, VEGF inhibitor ki67, SOMm 230
3. IGF1 –Inhibitor, MIBG-I-131

NET Octreotip

STT2 + 3+, 5+

SOM230 – Paseoreot

- Pit – Potential Tumor IGF-1 Inhibitor
- Insulin Other?
- Lanreotide

Short/Long Term

Angiogenesis vs Clinical Responses

Possum(sp) Score applied to NET, Surgical Points, Age, AlBuci

Resources

Resources Needed – Space/$$$